ABM Therapeutics’ ABM-168 Begins Phase I Dosing in the US for Advanced Solid Tumors
Shanghai-based ABM Therapeutics, Inc. has announced the commencement of the first patient enrollment and dosing...
Kangrui Health Partners with West China Second University Hospital for Pediatric Care Innovation
Kangrui Health, a leading data and intelligence application company based in Beijing, has entered into...
China’s CDE Releases 69th Batch of Generic Chemical Reference Preparations for Public Review
The Center for Drug Evaluation (CDE) in China has released the 69th batch of chemical...
Innovent Biologics’ GFH925 Earns Breakthrough Therapy Designation for KRASG12C CRC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Innovent Biologics’ (HKG: 1801) Category...
CARsgen Therapeutics’ AB011 and Tecentriq Combo Gets NMPA Approval for Gastric Cancer Treatment
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
Fujian Cosunter Pharmaceutical Completes Enrollment in Phase II/III Trial for GST-HG171/Ritonavir
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the completion of 1,200 patient...
BeiGene Reports Q1 2023 Financial Growth, Advances Pipeline with Global Expansion Plans
China-based BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has reported financial results for the...
China’s Regulatory Bodies Unveil Guidelines to Strengthen Supervision of Medical Aesthetic Industry
The State Administration for Market Regulation, National Health Commission, National Administration of Traditional Chinese Medicine,...
Medisan Pharmaceutical Secures PPAR Agonist Technology from China Pharmaceutical University
Harbin Medisan Pharmaceutical Co., Ltd (SHE: 002900) has announced a significant patent and technology transfer...
Meihua International Medical Expands with New Healthcare Industrial Park in Hainan
Meihua International Medical Technologies Co., Ltd (NASDAQ: MHUA), has announced the acquisition of a land...
Ascletis Pharma’s ASC40 Meets Acne Treatment Goals in Phase II Trial
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its first-in-class, once-daily oral fatty acid...
BDgene Technology’s BD111 Receives Tacit Approval for HSV-1 Keratitis Trial
Shanghai BDgene Technology Co., Ltd has announced that it has received tacit clinical trial approval...
SanReno Therapeutics Completes Dosing in Kidney Disease Trial for BION-1301
SanReno Therapeutics, a China-based joint venture (JV) specializing in nephropathy treatments, has announced the completion...
Qilu Pharmaceutical Launches First Generic Iressa in the US Market
China-based Qilu Pharmaceutical has announced the market launch of its generic version of AstraZeneca’s (AZ,...
NeuExcell Therapeutics Secures Over $14.5 Million in Pre-Series A+ Funding for Neurological Treatments
NeuExcell Therapeutics, a Sino-US biotech company specializing in treatments for neurological damage and degenerative diseases,...
Transcenta’s Osemitamab Achieves Full Enrollment in Phase II Gastric Cancer Study
Transcenta Holding Limited (HKG: 6628), a China-based biopharmaceutical company, has announced the completion of enrollment...
TYK Medicines’ TY-9591 Gains CDE Green Light for Pivotal Phase II Study in NSCLC with Brain Metastases
Shanghai-based TYK Medicines has announced that it has received the green light from the Center...
NMPA Transitions Desloratadine, Loratadine, Ambroxol, and Naproxen to OTC Status
The National Medical Products Administration (NMPA) has indicated on its website that four products will...
Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies
Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study...
Cellular Biomedicine Group Inc. and Janssen Biotech, Inc. Announce Global Collaboration for CAR-T Therapies
China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG), emerging from a merger deal in...